Turkiye Klinikleri Journal of Dermatology

.: ORIGINAL RESEARCH
Evaluation of the Diagnostic Significance of Some Biomarkers in Pruritic Dermatological Diseases: A Case-Control Study
Kaşıntılı Dermatolojik Hastalıklarda Bazı Biyobelirteçlerin Tanısal Öneminin Değerlendirilmesi: Bir Vaka Kontrol Çalışması
Neşe Başak TÜRKMENa, Dursun TÜRKMENb, Hande YÜCEa, Mücahit MARSAKb, Zübeyde TANRIVERDİa, Songül ÜNÜVARa
aDepartment of Pharmaceutical Toxicology, İnönü University Faculty of Pharmacy, Malatya, TURKEY
bDepartment of Dermatology, İnönü University Faculty of Medicine, Malatya, TURKEY
Turkiye Klinikleri J Dermatol. 2021;31(2):86-92
doi: 10.5336/dermato.2021-81122
Article Language: EN
ABSTRACT
Objective: Indolamine-2,3-dioxygenase (IDO), neopterin, periostin, tenascin-C (TN-C), chitinase-3-like protein 1 (CHI3L1/YKL- 40) YKL-40 have been previously described as diagnostic markers for a number of pathologies. The aim of our study is to compare the levels of some immune system-related biomarkers in itchy dermatological diseases with healthy people and to evaluate the diagnostic importance of these markers in dermatological diseases. Material and Methods: Our study included 55 patients diagnosed with neurodermatitis, generalised pruritus and lichen planus. The control group was composed of 30 healthy adult volunteers with no history of allergic skin conditions. All participants provided informed consent for the use of their medical data in the study. The serum samples were centrifuged. Centrifuged samples were stored at -80 °C. IDO, neopterin, periostin, TN-C, YKL-40 levels were determined by an enzyme-linked immunosorbent assay. The Mann- Whitney U test, Kruskal-Wallis test, and Conover post-hoc method were used for statistical analysis. Results: Demographic characteristics were recorded and no statistically significant difference was found between demographic differences. IDO, neopterin, periostin, TN-C, YKL-40 levels were higher in patients than in controls (p<0.05). The Th1/Th2-mediated immune response activation has been observed in allergic skin diseases. A positive correlation was found between all measured parameters (p<0.01). Conclusion: In our study, non-invasive current biomarkers that can be used in the diagnosis of dermatological pathologies yielded significant results. We found higher levels of serum biomarkers in patients compared to controls. It remains uncertain whether the examined protein is related only to inflammation or is released also as a result of specific biochemical processes due to allergy. However, these indicators may still have an important place in terms of early diagnosis.

Keywords: Indoleamine-2,3-dioxygenase; neopterin; periostin; pruritic diseases; tenascin-C
ÖZET
Amaç: İndolamin-2,3-dioksijenaz (IDO), neopterin, periostin, tenascin-C (TN-C), kitinaz-3-benzeri protein 1 (CHI3L1/YKL-40), daha önce bir dizi patolojinin tanısal belirteçleri olarak tanımlanmıştı. Çalışmamızın amacı, kaşıntılı dermatolojik hastalıklarda immün sistem ilişkili bazı biyobelirteçlerin düzeylerini sağlıklılarla karşılaştırmak ve bu belirteçlerin dermatolojik hastalıklardaki tanısal önemini değerlendirmektir. Gereç ve Yöntemler: Çalışmamıza nörodermatit, jeneralize kaşıntı, liken planus tanısı almış 55 hasta dâhil edildi. Kontrol grubu, alerjik cilt rahatsızlığı öyküsü olmayan 30 sağlıklı yetişkin gönüllüden oluşturuldu. Tüm katılımcılardan, çalışmada tıbbi verilerinin kullanılması için bilgilendirilmiş onam alındı serum örnekleri santrifüjlendi. Santrifüjlenen örnekler -80 °C'de saklandı. IDO, neopterin, periostin, TN-C, YKL-40 seviyeleri, enzime bağlı immünosorbent deneyi ile belirlendi. İstatistiksel analiz için Mann-Whitney U testi, Kruskal- Wallis testi ve Conover 'post hoc' yöntemi kullanıldı. Bulgular: Demografik özellikler kaydedildi ve demografik farklılıklar arasında istatistiksel olarak anlamlı bir fark bulunmadı. IDO, neopterin, periostin, TN-C YKL-40 seviyeleri hastalarda kontrole göre yüksekti (p<0.05). Alerjik cilt hastalıklarında Th1/Th2 aracılı immün yanıt aktivasyonu gözlenmiştir. Ölçülen tüm parametreler arasında pozitif yönde bir korelasyon bulundu (p<0.01). Sonuç: Çalışmamızda, dermatolojik patolojilerin tanısında kullanılabilen noninvaziv güncel biyobelirteçler önemli sonuçlar vermiştir. Kontrollere kıyasla hastalarda daha yüksek serum biyobelirteç seviyeleri bulduk. İncelenen proteinin yalnızca iltihaplanma ile ilişkili olup olmadığı veya aynı zamanda alerjiye bağlı spesifik biyokimyasal süreçlerin bir sonucu olarak da salgılanıp salgılanmadığı belirsizliğini korumaktadır. Ancak bu göstergeler, erken tanı açısından hâlâ önemli bir yere sahip olabilir.

Anahtar Kelimeler: İndolamin-2,3-dioksijenaz; neopterin; periostin; kaşıntılı hastalıklar; tenascin-C
REFERENCES:
  1. Fonacier LS, Dreskin SC, Leung DY. Allergic skin diseases. J Allergy Clin Immunol. 2010; 125(2 Suppl 2):S138-49. [Crossref]  [PubMed] 
  2. Murota H, Lingli Y, Katayama I. Periostin in the pathogenesis of skin diseases. Cell Mol Life Sci. 2017;74(23):4321-8. [Crossref]  [PubMed] 
  3. Kuwatsuka Y, Murota H. Involvement of periostin in skin function and the pathogenesis of skin diseases. Adv Exp Med Biol. 2019; 1132:89-98. [Crossref]  [PubMed] 
  4. Ünüvar S, Aslanhan H, Tanrıverdi Z, Karakuş F. The relationship between neopterin and hepatitis B surface antigen positivity. Pte ridines. 2018;29(1):1-5. [Crossref] 
  5. Ünüvar S, Erge D, Kılıçarslan B, Gözükara Bağ HG, Çatal F, Girgin G, et al. Neopterin levels and indoleamine 2,3-dioxygenase activity as biomarkers of immune system activation and childhood allergic diseases. Ann Lab Med. 2019;39(3):284-90. [Crossref]  [PubMed]  [PMC] 
  6. Khattab FM, Said NM. Chitinase-3-like protein 1 (YKL-40): novel biomarker of lichen planus. Int J Dermatol. 2019;58(9):993-6. [Crossref]  [PubMed] 
  7. Midwood KS, Chiquet M, Tucker RP, Orend G. Tenascin-C at a glance. J Cell Sci. 2016; 129(23):4321-27. [Crossref]  [PubMed] 
  8. von Bubnoff D, Bieber T. The indoleamine 2,3-dioxygenase (IDO) pathway controls allergy. Allergy. 2012;67(6):718-25. [Crossref]  [PubMed] 
  9. Masuoka M, Shiraishi H, Ohta S, Suzuki S, Arima K, Aoki S, et al. Periostin promotes chro nic allergic inflammation in response to Th2 cytokines. J Clin Invest. 2012;122(7):2590-600. [Crossref]  [PubMed]  [PMC] 
  10. Shiraishi H, Masuoka M, Ohta S, Suzuki S, Arima K, Taniguchi K, et al. Periostin contributes to the pathogenesis of atopic dermatitis by inducing TSLP production from keratinocytes. Allergol Int. 2012;61(4):563-72. [Crossref]  [PubMed] 
  11. Izuhara K, Nunomura S, Nanri Y, Ogawa M, Ono J, Mitamura Y, et al. Periostin in inflammation and allergy. Cell Mol Life Sci. 2017; 74(23):4293-303. [Crossref]  [PubMed] 
  12. Yamaguchi Y. Periostin in Skin Tissue Skin-Related Diseases. Allergol Int. 2014;63(2):161-70. [Crossref]  [PubMed] 
  13. Sung M, Lee KS, Ha EG, Lee SJ, Kim MA, Lee SW, et al. An association of periostin levels with the severity and chronicity of atopic dermatitis in children. Pediatr Allergy Immunol. 2017;28(6):543-50. [Crossref]  [PubMed] 
  14. Ozceker D, Yucel E, Sipahi S, Dilek F, Ozkaya E, Guler EM, et al. Evaluation of periostin level for predicting severity and chronicity of childhood atopic dermatitis. Postepy Dermatol Alergol. 2019;36(5):616-9. [Crossref]  [PubMed]  [PMC] 
  15. Kou K, Okawa T, Yamaguchi Y, Ono J, Inoue Y, Kohno M, et al. Periostin levels correlate with disease severity and chronicity in patients with atopic dermatitis. Br J Dermatol. 2014; 171(2):283-91. [Crossref]  [PubMed] 
  16. Yamaguchi Y, Ono J, Masuoka M, Ohta S, Izuhara K, Ikezawa Z, et al. Serum periostin levels are correlated with progressive skin sclerosis in patients with systemic sclerosis. Br J Dermatol. 2013;168(4):717-25. [Crossref]  [PubMed] 
  17. Hashimoto T, Kursewicz CD, Fayne RA, Nanda S, Shah SM, Nattkemper L, et al. Pathophysiologic mechanisms of itch in bullous pemphigoid. J Am Acad Dermatol. 2020;83(1):53-62. [Crossref]  [PubMed] 
  18. Hashimoto T, Satoh T, Yokozeki H. Pruritus in ordinary scabies: IL-31 from macrophages induced by overexpression of thymic stromal lymphopoietin and periostin. Allergy. 2019; 74(9):1727-37. [Crossref]  [PubMed] 
  19. Maraee AH, Farag AG, El Tahmody MA, Metawea, HY. Tenascin-C expression in lichen planus. Menoufia Med. J. 2015;28(2):514-20. [Crossref] 
  20. Ogawa K, Ito M, Takeuchi K, Nakada A, Heishi M, Suto H, et al. Tenascin-C is upregulated in the skin lesions of patients with atopic derma titis. J Dermatol Sci. 2005;40(1):35-41. [Crossref]  [PubMed] 
  21. Simon D, Aeberhard C, Erdemoglu Y, Simon HU. Th17 cells and tissue remodeling in atopic and contact dermatitis. Allergy. 2014;69(1): 125-31. [Crossref]  [PubMed] 
  22. Latijnhouwers MA, Bergers M, Kuijpers AL, van der Vleuten CJ, Dijkman H, van de Kerkhof PC, et al. Tenascin-C is not a useful marker for disease activity in psoriasis. Acta Derm Venereol. 1998;78(5):331-4. [Crossref]  [PubMed] 
  23. Kusubata M, Hirota A, Ebihara T, Kuwaba K, Matsubara Y, Sasaki T, et al. Spatiotemporal changes of fibronectin, tenascin-C, fibulin-1, and fibulin-2 in the skin during the development of chronic contact dermatitis. J Invest Dermatol. 1999;113(6):906-12. [Crossref]  [PubMed] 
  24. Xie Z, Zhang M, Xiong W, Wan HY, Zhao XC, Xie T, et al. Immunotolerant indoleamine-2,3-dioxygenase is increased in condyloma acuminata. Br J Dermatol. 2017;177(3):809-17. [Crossref]  [PubMed] 
  25. Schallreuter KU, Salem MA, Gibbons NC, Maitland DJ, Marsch E, Elwary SM, et al. Blunted epidermal L-tryptophan metabolism in vitiligo affects immune response and ROS scavenging by Fenton chemistry, part 2: Epidermal H2O2/ONOO(-)-mediated stress in vitiligo hampers indoleamine 2,3-dioxygenase and aryl hydrocarbon receptor-mediated immune response signaling. FASEB J. 2012; 26(6):2471-85. [Crossref]  [PubMed] 
  26. Scheler M, Wenzel J, Tüting T, Takikawa O, Bieber T, von Bubnoff D. Indoleamine 2,3-dioxygenase (IDO): the antagonist of type I interferon-driven skin inflammation? Am J Pathol. 2007;171(6):1936-43. [Crossref]  [PubMed]  [PMC] 
  27. Brunner PM, Israel A, Leonard A, Pavel AB, Kim HJ, Zhang N, et al. Distinct transcriptomic profiles of early-onset atopic dermatitis in blood and skin of pediatric patients. Ann Allergy Asthma Immunol. 2019;122(3):318-330.e3. [Crossref]  [PubMed] 
  28. Zinkevičienė A, Kainov D, Girkontaitė I, Lastauskienė E, Kvedarienė V, Fu Y, et al. Activation of Tryptophan and Phenylalanine Catabolism in the Remission Phase of Allergic Contact Dermatitis: A Pilot Study. Int Arch Allergy Immunol. 2016;170(4):262-8. [Crossref]  [PubMed] 
  29. Salomon J, Piotrowska A, Matusiak Ł, Dzięgiel P, Szepietowski JC. Chitinase-3-like Protein 1 (YKL-40) Is Expressed in Lesional Skin in Hid radenitis Suppurativa. In Vivo. 2019;33(1): 141-3. [Crossref]  [PubMed]  [PMC] 
  30. Abu El-Hamd M, Adam El Taieb M, Mahmoud AA, Mahmoud Samy O. Serum YKL-40 in patients with psoriasis vulgaris treated by narrow-band UVB phototherapy. J Dermatolog Treat. 2019;30(6):545-8. [Crossref]  [PubMed] 
  31. Salomon J, Matusiak Ł, Nowicka-Suszko D, Szepietowski JC. Chitinase-3-like protein 1 (YKL-40) Reflects the severity of symptoms in atopic dermatitis. J Immunol Res. 2017; 2017:5746031. [Crossref]  [PubMed]  [PMC] 
  32. Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev. 2006;15(2):194-202. [Crossref]  [PubMed] 

Login



Contact


Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 119 - 123
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com